Intro

This chapter delves into the history and development of monoamine oxidase inhibitors, highlighting the FDA approval of Iproniazid in 1958 and its unexpected mood-enhancing properties. It also introduces other MAOIs and sets the groundwork for discussions on treatment-resistant depression in future episodes.